SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Palintest launches Molendotech bathing water test

15 May 2018 07:00

RNS Number : 9469N
Frontier IP Group plc
15 May 2018
Β 

RNS REACH / RNS

AIM: FIPP

15 May 2018

Β 

Frontier IP Group Plc

("Frontier IP" or the "Group")

Β 

Β 

Portfolio news - Palintest launches Molendotech bathing water test

Β 

Β 

Frontier IP, which specialises in commercialising university intellectual property, today announces that Palintest, a subsidiary of FTSE 100 group Halma plc, is launching Siren BW, a water testing kit developed by portfolio company Molendotech, a spin out from the University of Plymouth.

Β 

It is the first commercial application for Molendotech's novel test able to identify the concentration of faecal bacteria in water. Currently, it can take two days for local authorities and environmental agencies to assess the quality of recreational water because samples must be sent to a laboratory. Palintest's field-ready kit produces a result in less than 30 minutes and is simple enough to be used at the sample point.

Β 

The kit is initially available in the UK and Ireland, with roll out to continental Europe and the US planned.

Β 

Further applications are now being developed in collaboration with Palintest to leverage the real-time availability of pathogen risk in water. It has a wide range of potential uses, including potable water and in food and beverage production.

Β 

Molendotech was incorporated less than a year ago to develop and commercialise the work of Simon Jackson, Professor of Environment and Human Health within the University of Plymouth's Peninsula Schools of Medicine and Dentistry.

Β 

Frontier IP chief executive officer Neil Crabb said: "We're delighted the agreement with Palintest, announced earlier this year, is bearing fruit so quickly. It has taken less than a year from Molendotech joining our portfolio to the commercial launch of its first product."

Β 

Director of Molendotech, Professor Simon Jackson, said: "Water quality is a global issue and fundamental to human and public health. Unfortunately, traditional, lab-based methods for testing water quality, particularly for faecal contamination, do not deliver the kind of rapid results required for in-situ investigation and decision-making. With this breakthrough, however, environmental agencies will be able to gain a much clearer understanding of water quality, which could lead to better and more effective management of beaches and other recreational bathing waters, and faster identification of sources of pollution."

Β 

Open Innovation Product Manager at Palintest Ian Leahy said: "The opportunity to bring our ability to produce rugged, simple-to-use water quality testing kits together with this exciting Molendotech innovation is a perfect example of two organisations collaborating to answer a clear customer need in the markets we already serve. For many years we sought opportunities to deliver simple, real-time microbiological risk screening at the point of use and I'm excited to say we are finally at that point now."

Β 

Β 

For more product details, please contact ian.leahy@palintest.com

Β 

Β 

ENQUIRIES

Β 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

andrew.johnson@frontierip.co.uk

Company website:Β www.frontierip.co.uk

Β 

M: 07464 546 025

Cenkos Securities plc (Nominated Adviser and Joint Broker)

T: 0131 220 6939

Neil McDonald / Beth McKiernan

Β 

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Lucy Williams

Β 

Kreab (Financial PR)

T: 020 7074 1800

Robert Speed / Matthew Jervois

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of equity stakes and licence income from by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

Frontier IP and the University of Plymouth:

Frontier IP has forged a strong relationship with the University of Plymouth to commercialise intellectual property. Other collaborations include:

Β· Fieldwork Robotics: developing advanced soft robotics for harvesting fruit and vegetables. The technology has attracted strong industry interest.

Β· The Vaccine Group: work includes creating novel vaccines to prevent viruses from jumping the species barrier from animals to humans

Β· Pulsiv Solar: US and European patents granted on its novel technology to improve the energy efficiency of photovoltaic cells and power conversion

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
NRAGIGDUUXBBGIS
Date   Source Headline
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes
24th Sep 20255:12 pmRNSHolding(s) in Company
13th Jun 20257:00 amRNSStrategic partnership for Cambridge innovation hub
10th Jun 20257:00 amRNS-RAlusid signs international distribution agreement
6th May 20257:00 amRNS-RTVG's vaccine candidate enters animal trials
16th Apr 20257:00 amRNS-RSyva signs option to license agreement with TVG
2nd Apr 20254:47 pmRNSDirector/PDMR Shareholding
31st Mar 20251:02 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSUnaudited Half Year Results
24th Mar 20257:00 amRNSCamGraphIC secures €25 million in Series A funding
18th Mar 20257:00 amRNS-RPulsiv wins PSMA’s Global Energy Efficiency Award
25th Feb 20257:00 amRNS-RGraphEnergyTech collaboration & Innovate UK grant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.